Cenobamate is a small molecule drug indicated to treat partial onset seizures in adults. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels.
- Mechanism
- Curator reviewed · 3 references
Cenobamate inhibits voltage gated sodium channels and is a positive GABAA modulator. However, the exact mechanism of action remains unknown. Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.
- Primary indication
- Cenobamate is indicated for the treatment of partial onset seizures in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C10H10ClN5O2 · 267.67 g/mol (avg)
- First approval
- Canada, 2025 · United States, 2020 · European Union, 2021
- Code names
- YKP-3089
- Brand names
Resolves to
GFHAXPJGXSQLPT-VIFPVBQESA-NSMILESNC(=O)O[C@@H](CN1N=CN=N1)C1=C(Cl)C=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Cenobamate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account